AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9105229
Drug: 0.015-0.32 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015-0.32 g/kg 5% rHb1.1 (n = 34)
Trial: 2029982
Drug: Kava Extract
RxNorm normalized name: Kava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava Extract WS 1490 (3 X 100 mg/day)
Trial: 28420440
Drug: AHSCT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHSCT treatment
Trial: 28420440
Drug: Insulin-only treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-only treatment
Trial: 15303783
Drug: Desonide (cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desonide (cream, ointment, or lotion formulation)
Trial: 10553820
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) 40 ppm
Trial: 7872445
Drug: Ceftriaxone, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 2 g/day for adults and 50 mg/kg/day for children, intravenously once a day for three days
Trial: 7872445
Drug: Chloramphenicol, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol, 60 mg/kg/day orally four times a day until defervescence, followed by 40 mg/kg/day for a total of 14 days
Trial: 1982289
Drug: Voluntary plane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary plane flights in the two months following treatment
Trial: 31451913
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG)
Trial: 31451913
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg calcium + 800 IU vitamin D (placebo group; PG)
Trial: 25959549
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (CBT) for BED
Trial: 24147266
Drug: Aspirin continued
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continued (Group 1)
Trial: 24147266
Drug: Aspirin stopped
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin stopped (Group 2)
Trial: 24147266
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (Group 3 - Control)
Trial: 21319007
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 2.5 mg/day
Trial: 17245174
Drug: Fenofibrate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (5 mg/kg)
Trial: 10197141
Drug: Cetirizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (20 mg, twice the daily recommended dose)
Trial: 9223914
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy (3 x 10(6) U recombinant IFN alpha, subcutaneously three times a week, every other day, for a total of 12 doses)
Trial: 1203699
Drug: Hypertonic glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic glucose, fructose, and sorbitol solutions (IV)
Trial: 31838497
Drug: TE (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TE (0.1 mg/day) + IMP (200 mg/day for 12 days)
Trial: 29319063
Drug: Supervised Toothbrushing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised Toothbrushing (STB) in Ultra-Conservative Treatment (UCT)
Trial: 29319063
Drug: Conventional Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Restorative Treatment (CRT) with Unsupervised Toothbrushing (USTB)
Trial: 29319063
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) with Unsupervised Toothbrushing (USTB)
Trial: 29319063
Drug: No-treatment with
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment with Unsupervised Toothbrushing (USTB)
Trial: 22187767
Drug: palanosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palanosetron (0.25 mg) IV
Trial: 22187767
Drug: granisetron (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granisetron (3.0 mg) IV
Trial: 22187767
Drug: ondansetron (8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (8.0 mg) IV
Trial: 14998843
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy (gemcitabine, vinorelbine, taxanes)
Trial: 14998843
Drug: Carboplatin-based or
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-based or low-dose cisplatin-based doublets
Trial: 14998843
Drug: New biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New biological agents
Trial: 12579942
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of salbutamol
Trial: 8314287
Drug: Cefuroxime (4.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (4.05 g/die)
Trial: 8314287
Drug: Cefotiam (5.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (5.30 g/die)
Trial: 8314287
Drug: Cefotiam with
RxNorm normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotiam with furosemide (0.5 mg/kg body weight) intravenously
Trial: 8314287
Drug: Cefuroxime with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime with furosemide (0.5 mg/kg body weight) intravenously
Trial: 3285835
Drug: furosemide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furosemide (60 mg)
Trial: 29141548
Drug: Cognitive Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Training (CT) program, conducted twice a week for six months.
Trial: 28766500
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of memantine 10 mg
Trial: 28766500
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of memantine 10 mg
Trial: 19794994
Drug: Epidural PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural PCA (ropivacaine 0.2% + fentanyl 5 microg/mL at 4 mL/hr)
Trial: 19794994
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA (ketorolac 0.2 mg/kg + fentanyl 15 microg/mL at 1 mL/hr)
Trial: 16874871
Drug: B-OAzM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-OAzM (omeprazole 20 mg, bismuth subcitrate 240 mg, azithromycin 250 mg, and metronidazole 500 mg, all twice daily for 1-wk)
Trial: 16874871
Drug: B-OAM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-OAM (omeprazole 20 mg, bismuth subcitrate 240 mg, amoxicillin 1 g, and metronidazole 500 mg, all twice daily for 2-wk)
Trial: 12775734
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg (intermittent)
Trial: 12775734
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg (intermittent)
Trial: 12775734
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg (continuous)
Trial: 12775734
Drug: Chemotherapy (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (carboplatin and paclitaxel)
Trial: 10835489
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1000 mg/day
Trial: 10835489
Drug: High-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta-carotene
Trial: 10835489
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg beta-carotene, 0 mg vitamin C)
Trial: 10835489
Drug: Beta-carotene 3
RxNorm normalized name: beta-carotene 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene 3 mg/day
Trial: 9353803
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation (twice-daily treatment sessions for 3 months)
Trial: 9353803
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily retention of the control probe)
Trial: 8384170
Drug: Dexfenfluramine (dFE:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (dFE: 30 mg per os)
Trial: 3885152
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E treatment (mean serum level 5.1 mg/dL)
Trial: 25543610
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (loading and unloading mini-implants)
Trial: 23062766
Drug: 180 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 μg/d MK-7 supplementation
Trial: 23062766
Drug: 360 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 μg/d MK-7 supplementation
Trial: 23062766
Drug: MK-7 supplementation
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 supplementation (both doses)
Trial: 12456604
Drug: Post GnRH
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post GnRH agonist rise in FSH and LH levels
Trial: 10479120
Drug: CMV gB
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB vaccine with MF59
Trial: 10479120
Drug: CMV gB
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB vaccine with alum
Trial: 10479120
Drug: CMV gB
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB vaccine with MF59 (fourth dose)
Trial: 8955652
Drug: Topotecan (TPT)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (TPT) administered as a 30-minute infusion daily for 5 days, with doses of 0.75 mg/m2, 1 mg/m2, and 0.75 mg/m2 in combination with cisplatin (CDDP) at doses of 50 mg/m2 and 75 mg/m2.
Trial: 8955652
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) administered either before TPT on day 1 or after TPT on day 5.
Trial: 6309730
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg, single dose)
Trial: 6309730
Drug: Cefaclor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (500 mg, single dose)
Trial: 27070434
Drug: Gabapentin (300-2700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300-2700 mg daily)
Trial: 25093663
Drug: Ultrasound-guided Transversus
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided Transversus Abdominis Plane (TAP) block (levobupivacaine = 150 mg)
Trial: 25093663
Drug: Continuous Wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Wound Infusion (CWI) (levobupivacaine = 150 mg first day and 12.5 mg/h thereafter)
Trial: 22928872
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (three weekly physical exercise sessions lasting 60-75 minutes each for 16 weeks)
Trial: 20071838
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% infiltration (20 ml)
Trial: 8584192
Drug: Fentanyl 0.005
RxNorm normalized name: fentanyl 0.005 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.005 mg/kg + Midazolam 0.2 mg/kg
Trial: 8584192
Drug: Fentanyl 0.005
RxNorm normalized name: fentanyl 0.005 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.005 mg/kg + Propofol 2.5 mg/kg
Trial: 8584192
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg + Propofol 2.0 mg/kg
Trial: 31537562
Drug: Treatment-related complications
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related complications
Trial: 25890211
Drug: Rupatadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine (10 mg, 20 mg, 40 mg single doses; 10 mg multiple doses)
Trial: 22314633
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) 5 g twice daily, n = 22
Trial: 22314633
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus CHM (Kun Bao Wan) 5 g twice daily plus sessions of acupuncture, n = 20
Trial: 22314633
Drug: Hormone therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy, n = 15
Trial: 19032447
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride (300 mg/day)
Trial: 19032447
Drug: Rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole sodium (20 mg/day)
Trial: 12604982
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) 10^9 orally twice daily for 21 days in infants <1500 g
Trial: 12604982
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) for 8 days in infants 1500 to 1999 g
Trial: 12604982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LGG treatment) for infants <1500 g
Trial: 12604982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LGG treatment) for infants 1500 to 1999 g
Trial: 10690513
Drug: HuM195 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HuM195 treatment
Trial: 10690513
Drug: HuM195 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HuM195 treatment after RA alone
Trial: 10690513
Drug: HuM195 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HuM195 treatment in newly diagnosed APL
Trial: 10690513
Drug: HuM195 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HuM195 treatment in second or third remission
Trial: 9327292
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg daily)
Trial: 2878680
Drug: xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol 200 mg
Trial: 30028484
Drug: High-protein enteral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein enteral diet providing 3 g ß‐glucan
Trial: 30028484
Drug: Placebo diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diet with 3 g maltodextrin
Trial: 24756009
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg/day) plus metadoxine (500 mg three times daily)
Trial: 22322966
Drug: Topical α‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical α‐2 agonist brimonidine
Trial: 22322966
Drug: Goal‐directed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal‐directed intravenous administration of 5% albumin
Trial: 22322966
Drug: Goal‐directed administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal‐directed administration of lactated Ringer's solution
Trial: 20196184
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (6-9 months)
Trial: 16183427
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg) plus insulin
Trial: 12955901
Drug: Novel antipsychotic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antipsychotic drugs
Trial: 10727880
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of co-artemether and mefloquine
Trial: 8855983
Drug: IL-2 with
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 with levamisole (50 mg t.d.s. p.o. on days 1-3 on alternate weeks)
Trial: 30575489
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg)
Trial: 27798337
Drug: GOS +
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS + 0.2 g 2'‐FL/L
Trial: 27798337
Drug: GOS +
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS + 1.0 g 2'‐FL/L
Trial: 20061328
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFA) capsules, 1240 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid, for 5-7 days prior to surgery and post-operatively until hospital discharge
Trial: 20061328
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsules for 5-7 days prior to surgery and post-operatively until hospital discharge
Trial: 12433819
Drug: R (ritonavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R (ritonavir) 400 mg given simultaneously with S (saquinavir) 800 mg
Trial: 12433819
Drug: N (nelfinavir)
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N (nelfinavir) 750 mg given simultaneously with S (saquinavir) 800 mg
Trial: 12433819
Drug: R (ritonavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R (ritonavir) 400 mg
Trial: 10725786
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (2 mg/kg/day) for 12 weeks
Trial: 7795774
Drug: 2.5% selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% selenium sulfide lotion
Trial: 1954072
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 11 days
Trial: 1954072
Drug: Digoxin 1
RxNorm normalized name: DIGOXIN 125MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 1 mg alone (control)
Trial: 7007474
Drug: Preseasonal intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseasonal intranasal short ragweed (SRW) immunotherapy, sprayed SRW solutions intranasally six times a day for 12 weeks
Trial: 7007474
Drug: Preseasonal intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseasonal intranasal short ragweed (SRW) immunotherapy
Trial: 7007474
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with nebulized solutions containing buffer or histamine
Trial: 31402321
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus taselisib (4 mg orally, on a 5 days-on, 2 days-off schedule for 16 weeks)
Trial: 28647383
Drug: Agaricus bisporus
RxNorm normalized name: Agaricus bisporus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agaricus bisporus mushrooms (226 g)
Trial: 28647383
Drug: Meat (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat (28 g)
Trial: 25210140
Drug: Norovirus GI.1/GII.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum
Trial: 25210140
Drug: Norovirus GI.1/GII.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norovirus GI.1/GII.4 bivalent vaccine-like particle (VLP) vaccine
Trial: 21083671
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg every 4 weeks (n = 28)
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 35 mg
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 105 mg
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 210 mg